Laddar...
Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris
FMX101 4% minocycline is a hydrophobic, topical foam formulation of minocycline recently approved by the United States Food and Drug Administration (FDA) for the treatment of non-nodular inflammatory lesions in moderate-to-severe acne vulgaris. It was developed to harness the anti-inflammatory and a...
Sparad:
| I publikationen: | J Clin Aesthet Dermatol |
|---|---|
| Huvudupphovsmän: | , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Matrix Medical Communications
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7605387/ https://ncbi.nlm.nih.gov/pubmed/33144907 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|